$203.15
00.00%
Pre-Market: Jul 19, 5:07 PM EDT
15 minutes delayed
Comments
Loading...
ResMed
RMDNYSE
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
ResMed (NYSE:RMD) Stock, Analyst Ratings, Price Targets, Forecasts
ResMed Inc has a consensus price target of $225.77 based on the ratings of 20 analysts. The high is $300 issued by Baird on January 13, 2022. The low is $169 issued by Morgan Stanley on October 27, 2023. The 3 most-recent analyst ratings were released by Needham, Oppenheimer, and RBC Capital on June 24, 2024, April 26, 2024, and April 26, 2024, respectively. With an average price target of $212 between Needham, Oppenheimer, and RBC Capital, there's an implied 4.36% upside for ResMed Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
RBC Capital
Keybanc
Mizuho
UBS
1calculated from analyst ratings
Analyst Ratings for ResMed
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/25/2024 | Buy Now | — | Oppenheimer | Suraj Kalia | — | Downgrade | Outperform → Perform | Get Alert |
| 06/24/2024 | Buy Now | — | Citigroup | Mathieu Chevrier | — | Downgrade | Buy → Neutral | Get Alert |
| 06/24/2024 | Buy Now | 16.17% | Needham | Mike Matson | $236 → $236 | Reiterates | Buy → Buy | Get Alert |
| 04/26/2024 | Buy Now | -1.55% | Oppenheimer | Suraj Kalia | $205 → $200 | Maintains | Outperform | Get Alert |
| 04/26/2024 | Buy Now | -1.55% | RBC Capital | Craig Wong-Pan | $187 → $200 | Maintains | Sector Perform | Get Alert |
| 04/26/2024 | Buy Now | 17.15% | Keybanc | Brett Fishbin | $227 → $238 | Maintains | Overweight | Get Alert |
| 04/26/2024 | Buy Now | 16.17% | Needham | Mike Matson | $224 → $236 | Maintains | Buy | Get Alert |
| 04/01/2024 | Buy Now | 10.26% | Needham | Mike Matson | $215 → $224 | Maintains | Buy | Get Alert |
| 03/27/2024 | Buy Now | 5.83% | Mizuho | Anthony Petrone | $215 → $215 | Maintains | Buy | Get Alert |
| 02/06/2024 | Buy Now | 11.74% | Keybanc | Brett Fishbin | → $227 | Initiates | → Overweight | Get Alert |
| 01/30/2024 | Buy Now | 0.91% | Oppenheimer | Suraj Kalia | $185 → $205 | Maintains | Outperform | Get Alert |
| 01/30/2024 | Buy Now | 5.83% | Mizuho | Anthony Petrone | $195 → $215 | Maintains | Buy | Get Alert |
| 01/26/2024 | Buy Now | -4.01% | Mizuho | Anthony Petrone | $180 → $195 | Maintains | Buy | Get Alert |
| 01/25/2024 | Buy Now | -11.4% | UBS | Saul Hadassin | $175 → $180 | Maintains | Neutral | Get Alert |
| 01/25/2024 | Buy Now | -10.41% | RBC Capital | Craig Wong-Pan | $181 → $182 | Maintains | Sector Perform | Get Alert |
| 01/25/2024 | Buy Now | 5.83% | Needham | Mike Matson | $180 → $215 | Maintains | Buy | Get Alert |
| 01/09/2024 | Buy Now | -4.01% | JP Morgan | David Low | $160 → $195 | Maintains | Overweight | Get Alert |
| 10/31/2023 | Buy Now | -21.24% | Mizuho | Anthony Petrone | $180 → $160 | Maintains | Buy | Get Alert |
| 10/27/2023 | Buy Now | -16.81% | Morgan Stanley | Sean Laaman | → $169 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 10/16/2023 | Buy Now | -13.86% | Oppenheimer | Suraj Kalia | $275 → $175 | Maintains | Outperform | Get Alert |
| 10/12/2023 | Buy Now | -0.57% | RBC Capital | Craig Wong-Pan | $273 → $202 | Downgrade | Outperform → Sector Perform | Get Alert |
| 09/29/2023 | Buy Now | — | Wolfe Research | Mike Polark | — | Downgrade | Outperform → Peer Perform | Get Alert |
| 09/18/2023 | Buy Now | 13.22% | B of A Securities | Lyanne Harrison | $250 → $230 | Maintains | Buy | Get Alert |
| 09/13/2023 | Buy Now | -11.4% | Mizuho | Anthony Petrone | $255 → $180 | Maintains | Buy | Get Alert |
| 09/06/2023 | Buy Now | -11.4% | Needham | Mike Matson | → $180 | Upgrade | Hold → Buy | Get Alert |
| 09/05/2023 | Buy Now | -16.32% | UBS | Saul Hadassin | $265 → $170 | Downgrade | Buy → Neutral | Get Alert |
| 08/14/2023 | Buy Now | 34.38% | RBC Capital | Craig Wong-Pan | $284 → $273 | Maintains | Outperform | Get Alert |
| 08/04/2023 | Buy Now | 39.8% | RBC Capital | Craig Wong-Pan | → $284 | Reiterates | Outperform → Outperform | Get Alert |
| 08/04/2023 | Buy Now | 23.06% | B of A Securities | Lyanne Harrison | $260 → $250 | Maintains | Buy | Get Alert |
| 08/04/2023 | Buy Now | 27.98% | Keybanc | Matthew Mishan | $280 → $260 | Maintains | Overweight | Get Alert |
| 08/01/2023 | Buy Now | 39.8% | RBC Capital | Craig Wong-Pan | $262 → $284 | Upgrade | Sector Perform → Outperform | Get Alert |
| 05/22/2023 | Buy Now | 42.75% | UBS | Saul Hadassin | → $290 | Initiates | → Buy | Get Alert |
| 04/14/2023 | Buy Now | 25.52% | Mizuho | Anthony Petrone | → $255 | Initiates | → Buy | Get Alert |
| 04/13/2023 | Buy Now | 25.52% | Mizuho | Anthony Petrone | → $255 | Initiates | → Buy | Get Alert |
| 01/27/2023 | Buy Now | 27.98% | JP Morgan | David Low | $245 → $260 | Maintains | Overweight | Get Alert |
| 01/17/2023 | Buy Now | 20.6% | JP Morgan | David Low | → $245 | Upgrade | Neutral → Overweight | Get Alert |
| 10/28/2022 | Buy Now | 25.03% | RBC Capital | Craig Wong-Pan | $252 → $254 | Maintains | Sector Perform | Get Alert |
| 10/28/2022 | Buy Now | 37.83% | Keybanc | Matthew Mishan | $276 → $280 | Maintains | Overweight | Get Alert |
| 10/20/2022 | Buy Now | 27.98% | B of A Securities | Lyanne Harrison | $245 → $260 | Upgrade | Neutral → Buy | Get Alert |
| 10/12/2022 | Buy Now | 20.6% | Jefferies | Matthew Taylor | → $245 | Initiates | → Hold | Get Alert |
| 09/08/2022 | Buy Now | — | Citigroup | John Deakin-Bell | — | Upgrade | Neutral → Buy | Get Alert |
| 08/12/2022 | Buy Now | — | JP Morgan | David Low | — | Downgrade | Overweight → Neutral | Get Alert |
| 08/12/2022 | Buy Now | 24.05% | RBC Capital | Craig Wong-Pan | $246 → $252 | Downgrade | Outperform → Sector Perform | Get Alert |
| 06/15/2022 | Buy Now | 21.59% | RBC Capital | Craig Wong-Pan | $244 → $247 | Maintains | Outperform | Get Alert |
| 06/06/2022 | Buy Now | 20.11% | RBC Capital | Craig Wong-Pan | $233 → $244 | Upgrade | Sector Perform → Outperform | Get Alert |
| 04/29/2022 | Buy Now | 14.69% | RBC Capital | Craig Wong-Pan | $241 → $233 | Maintains | Sector Perform | Get Alert |
| 04/29/2022 | Buy Now | 35.86% | Keybanc | Matthew Mishan | $302 → $276 | Maintains | Overweight | Get Alert |
| 04/06/2022 | Buy Now | 37.83% | Wolfe Research | Mike Polark | → $280 | Initiates | → Outperform | Get Alert |
| 01/31/2022 | Buy Now | — | Citigroup | John Deakin-Bell | — | Upgrade | Neutral → Buy | Get Alert |
| 01/28/2022 | Buy Now | 18.63% | RBC Capital | Craig Wong-Pan | → $241 | Upgrade | Underperform → Sector Perform | Get Alert |
| 01/24/2022 | Buy Now | 32.91% | JP Morgan | David Low | $260 → $270 | Upgrade | Neutral → Overweight | Get Alert |
| 01/24/2022 | Buy Now | — | B of A Securities | Lyanne Harrison | — | Upgrade | Underperform → Neutral | Get Alert |
| 01/13/2022 | Buy Now | 15.19% | RBC Capital | Craig Wong-Pan | $227 → $234 | Maintains | Underperform | Get Alert |
| 01/13/2022 | Buy Now | 47.67% | Baird | Mike Polark | $270 → $300 | Upgrade | Neutral → Outperform | Get Alert |
| 01/13/2022 | Buy Now | — | CLSA | Andrew Paine | — | Upgrade | Outperform → Buy | Get Alert |
| 12/21/2021 | Buy Now | 48.66% | Keybanc | Matthew Mishan | → $302 | Upgrade | Sector Weight → Overweight | Get Alert |
| 12/06/2021 | Buy Now | — | Macquarie | David Bailey | — | Upgrade | Neutral → Outperform | Get Alert |
| 10/29/2021 | Buy Now | 11.74% | RBC Capital | — | — | Maintains | Underperform | Get Alert |
| 08/02/2021 | Buy Now | — | CLSA | — | — | Downgrade | Outperform → Sell | Get Alert |
| 08/02/2021 | Buy Now | — | Needham | Mike Matson | — | Downgrade | Buy → Hold | Get Alert |
| 07/28/2021 | Buy Now | 18.14% | Jefferies | Anthony Petrone | — | Upgrade | Underperform → Hold | Get Alert |
| 07/27/2021 | Buy Now | 17.15% | RBC Capital | — | — | Maintains | Underperform | Get Alert |
| 07/26/2021 | Buy Now | 21.09% | JP Morgan | David Low | — | Downgrade | Overweight → Neutral | Get Alert |
FAQ
What is the target price for ResMed (RMD) stock?
The latest price target for ResMed (NYSE:RMD) was reported by Oppenheimer on June 25, 2024. The analyst firm set a price target for $0.00 expecting RMD to fall to within 12 months (a possible -100.00% downside). 31 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ResMed (RMD)?
The latest analyst rating for ResMed (NYSE:RMD) was provided by Oppenheimer, and ResMed downgraded their perform rating.
When was the last upgrade for ResMed (RMD)?
The last upgrade for ResMed Inc happened on October 27, 2023 when Morgan Stanley raised their price target to $169. Morgan Stanley previously had an equal-weight for ResMed Inc.
When was the last downgrade for ResMed (RMD)?
The last downgrade for ResMed Inc happened on June 25, 2024 when Oppenheimer changed their price target from N/A to N/A for ResMed Inc.
When is the next analyst rating going to be posted or updated for ResMed (RMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ResMed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ResMed was filed on June 25, 2024 so you should expect the next rating to be made available sometime around June 25, 2025.
Is the Analyst Rating ResMed (RMD) correct?
While ratings are subjective and will change, the latest ResMed (RMD) rating was a downgraded with a price target of $0.00 to $0.00. The current price ResMed (RMD) is trading at is $203.15, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.